204 related articles for article (PubMed ID: 14744791)
1. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.
Ge Y; Jensen TL; Stout ML; Flatley RM; Grohar PJ; Ravindranath Y; Matherly LH; Taub JW
Cancer Res; 2004 Jan; 64(2):728-35. PubMed ID: 14744791
[TBL] [Abstract][Full Text] [Related]
2. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines.
Ge Y; Jensen TL; Matherly LH; Taub JW
Blood; 2003 Feb; 101(4):1551-7. PubMed ID: 12393509
[TBL] [Abstract][Full Text] [Related]
4. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
[TBL] [Abstract][Full Text] [Related]
5. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
Taub JW; Matherly LH; Stout ML; Buck SA; Gurney JG; Ravindranath Y
Blood; 1996 Apr; 87(8):3395-403. PubMed ID: 8605357
[TBL] [Abstract][Full Text] [Related]
6. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
[TBL] [Abstract][Full Text] [Related]
8. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.
Ge Y; LaFiura KM; Dombkowski AA; Chen Q; Payton SG; Buck SA; Salagrama S; Diakiw AE; Matherly LH; Taub JW
Leukemia; 2008 Mar; 22(3):521-9. PubMed ID: 18094719
[TBL] [Abstract][Full Text] [Related]
9. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Meijerink JP; Ebus ME; Peters GJ; Noordhuis P; Janka-Schaub GE; Armstrong SA; Korsmeyer SJ; Pieters R
Blood; 2003 Feb; 101(4):1270-6. PubMed ID: 12406912
[TBL] [Abstract][Full Text] [Related]
10. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
[TBL] [Abstract][Full Text] [Related]
11. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M
Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625
[TBL] [Abstract][Full Text] [Related]
12. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W
Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650
[TBL] [Abstract][Full Text] [Related]
13. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
[TBL] [Abstract][Full Text] [Related]
14. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.
Caldwell JT; Edwards H; Dombkowski AA; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2013; 8(7):e68601. PubMed ID: 23874683
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
17. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
19. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Bhalla K; McCrady C
Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
[TBL] [Abstract][Full Text] [Related]
20. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
